AbbVie Inc. P/B ratio

P/B ratio of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.


Highlights and Quick Summary

Current P/B ratio of AbbVie Inc. is 0.0 (as of December 30, 2019)
  • P/B ratio for the quarter ending March 30, 2020 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly P/B ratio decreased by NaN%
  • Annual P/B ratio for 2019 was 0.0 (a NaN% decrease from previous year)
  • Annual P/B ratio for 2018 was 0.0 (a -100.0% decrease from previous year)
  • Annual P/B ratio for 2017 was 30.81 (a 41.12% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of AbbVie Inc.

Most recent P/B ratioof ABBV including historical data for past 10 years.

Interactive Chart of P/B ratio of AbbVie Inc.

AbbVie Inc. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0 0.0 40.95 0.0
2017 30.81 21.59 19.25 20.82 30.81
2016 21.84 15.91 17.83 19.88 21.84
2015 24.4 18.48 19.78 67.81 24.4
2014 59.92 19.83 17.24 17.45 59.92
2013 18.68 19.88 18.58 22.08 18.68
2012 16.47 16.47 16.47 16.47 16.47
2011 16.47 16.47 16.47 16.47 16.47
2010 16.47
2009 16.47

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.